{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"10.7","value":"8.9"},{"groupId":"OG001","lowerLimit":"2.6","upperLimit":"10.8","value":"4.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Duration of PSA response was defined as the duration between the date of first document PSA response (i.e. \\>= 50% decrease in PSA from Baseline) and the earliest date of PSA progression, where date of PSA progression was defined as: 1) Where a decline from baseline was documented, date that a \\>= 25% increase in PSA and an absolute increase of 2 ng/mL or more from the nadir was documented and confirmed by a second consecutive value obtained at least 3 weeks later. Rises in PSA within the first 12 weeks of the date of first dose of randomized treatment were ignored; 2) Where no decline from baseline was documented, PSA progression was defined as a \\>= 25% increase from the baseline value along with an increase in absolute value of 2 ng/mL or more after 12 weeks from the date of first dose of randomized treatment (without confirmation) as specified in the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"}],"paramType":"MEDIAN","populationDescription":"PFS Full Analysis Set (PFS-FAS). Only participants with PSA progression were included in the analysis.","reportingStatus":"POSTED","timeFrame":"From date of first documented PSA response till 30 days safety fup, assessed up to approximately 32 months (Primary Analysis cut-off date = 27-Jan-2021)","title":"Duration of PSA Response","type":"SECONDARY","unitOfMeasure":"Months"}